Progenics Pharmaceuticals, Inc. (PGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.56-0.28 (-4.09%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close6.84
Bid6.61 x 3000
Ask7.05 x 2000
Day's Range6.52 - 7.09
52wk Range3.61 - 8.37
1y Target EstN/A
Market Cap459.1M
P/E Ratio (ttm)-12.94
Avg Vol (3m)1,560,931
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Bloomberg20 days ago

    Valeant’s Relistor Said to Draw Interest of Potential Buyers

    Valeant Pharmaceuticals International Inc.’s Relistor drug has attracted interest from other companies as the beleaguered Canadian firm works to reduce its debt load, people familiar with the matter said....

  • Associated Press21 days ago

    Progenics reports 2Q loss

    The Tarrytown, New York-based company said it had a loss of 8 cents per share. The biopharmaceutical company posted revenue of $8.5 million in the period. Progenics shares have decreased nearly 5 percent ...

  • GlobeNewswire21 days ago

    Progenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results

    On July 19, the Company Announced FDA Approval of RELISTOR ® Tablets, Triggering a $50 Million Milestone Ultra-Orphan Radiotherapeutic Candidate AZEDRA ® Registrational Trial Topline Results Expected Between ...